Daily Cardiology Research Analysis
Analyzed 238 papers and selected 3 impactful papers.
Summary
Analyzed 238 papers and selected 3 impactful articles.
Selected Articles
1. Single-cell multiomics and chromatin structure reveal gene-regulatory dynamics in heart failure.
This landmark multimodal single-cell atlas integrates transcriptomes, chromatin accessibility, histone marks, and 3D organization across failing and nonfailing human hearts. It defines cell type–specific regulatory programs and enhancer–gene links, bridging human genetics to mechanisms that may drive heart failure.
Impact: Provides a foundational, cell-resolved regulatory map of the human failing heart, enabling causal inference from GWAS and rational target discovery for precision therapeutics.
Clinical Implications: While not immediately practice-changing, the atlas prioritizes cell type–specific pathways and enhancer–gene pairs for drug development, biomarker discovery, and stratified trial design in heart failure.
Key Findings
- Generated cell type–resolved transcriptome, chromatin accessibility, histone modification, and chromatin organization maps from 13 nonfailing and 23 failing human hearts.
- Identified dynamic, disease-associated gene-regulatory programs in cardiomyocytes and fibroblasts, including chromatin reorganization.
- Mapped enhancer–gene interactions, enabling assignment of likely causal GWAS signals to specific cell types and pathways in heart failure.
Methodological Strengths
- Multimodal single-cell profiling spanning multiple chromatin layers across all cardiac chambers.
- Integration with genetic association data to infer causal cell type–specific mechanisms.
Limitations
- Cross-sectional tissue analysis limits inference on temporal causality and treatment effects.
- Modest sample size and potential confounders (e.g., medications, comorbidities) inherent to end-stage tissue studies.
Future Directions: Leverage enhancer–gene maps for perturbation studies, nominate druggable nodes per cell type, and develop biomarkers reflecting cell state transitions in heart failure.
Heart failure is a leading cause of morbidity and mortality, yet gene-regulatory mechanisms driving cell type-specific pathologic responses remain undefined. Here, we present the cell type-resolved transcriptomes, chromatin accessibility, histone modifications, and chromatin organization of 13 nonfailing and 23 failing human hearts across all cardiac chambers. Integrative analyses revealed dynamic changes in cell type composition, gene-regulatory programs, and chromatin organization, particularly in cardiomyocytes and fibroblasts. Mapping cell type-specific enhancer-gene interactions from these analyses enabled the illumination of likely causal genetic contributors to heart failure from genetic association data. Together, these findings provide multimodal gene-regulatory maps of the human heart in health and disease, offering a framework for designing precise, cell type-targeted therapies for treating heart failure.
2. S1P receptor 1 signaling reduces arterial thrombosis via up-regulation of endothelial thrombomodulin expression.
S1P1 activation upregulated endothelial thrombomodulin, reducing platelet adhesion and arterial thrombosis without prolonging bleeding in mice; low endogenous S1P increased thrombosis and was rescued by TM. In patients, higher S1P associated with lower thrombin levels, supporting translational relevance.
Impact: Reveals an endothelium-centered antithrombotic pathway that spares hemostasis, addressing a key trade-off in current antithrombotic therapy.
Clinical Implications: Therapeutics enhancing endothelial S1P1–thrombomodulin signaling may prevent arterial thrombosis with lower bleeding risk; biomarkers (S1P, TM) could aid risk stratification.
Key Findings
- S1P increased endothelial thrombomodulin via S1P1–PI3K signaling and reduced platelet adhesion under flow.
- In mice, S1P decreased arterial thrombosis without altering bleeding time; Sphk1 deficiency enhanced thrombosis and lowered endothelial TM, reversible by TM.
- In 74 CVD patients, higher S1P concentrations correlated with lower circulating thrombin, supporting translational relevance.
Methodological Strengths
- Convergent evidence across in vitro flow systems, in vivo mouse thrombosis/bleeding assays, and human cohort correlations.
- Mechanistic dissection implicating S1P1–PI3K–TM axis with genetic (Sphk1−/−) validation and rescue experiments.
Limitations
- Human data are cross-sectional with a modest sample size (n=74), limiting causal inference.
- Therapeutic translatability (dose, selectivity, off-targets) requires formal pharmacology and clinical trials.
Future Directions: Develop S1P1-biased agonists or TM inducers, evaluate endothelial target engagement and thrombosis–bleeding separation in large animals, and test biomarker-guided strategies clinically.
Sphingosine-1-phosphate (S1P) is a key mediator in the cardiovascular system with controversial effects on coagulation. We hypothesized that S1P reduces platelet adhesion and thrombus formation by up-regulating endothelial thrombomodulin (TM), an antithrombotic protein. S1P increased endothelial TM expression via S1P receptor 1 and phosphoinositide 3-kinase signaling. S1P reduced platelet adhesion on endothelial cells in flow-chamber experiments. In the absence of endothelial cells, S1P did not affect platelet activation. In mice, S1P enhanced endothelial TM expression and decreased in vivo arterial thrombus formation but did not change bleeding time. Conversely, sphingosine kinase 1-deficient mice with low S1P concentrations showed reduced endothelial TM expression and enhanced thrombus formation, reversible by TM treatment. In line with this, in an all-comer cohort of 74 patients with cardiovascular disease, higher S1P concentrations were associated with lower circulating thrombin concentrations. In conclusion, S1P inhibited thrombus formation in an endothelium- and TM-dependent manner. This might be a therapeutic target in prevention of thrombus formation without enhancing bleeding risk.
3. Long-term efficacy and safety of left atrial appendage closure vs. oral anticoagulation in atrial fibrillation: a meta-analysis of randomized controlled trials.
Across six RCTs (n=7004), LAAC increased ischemic stroke/systemic embolism versus OAC (RR 1.41) with no difference in mortality, major bleeding, or hemorrhagic stroke, while reducing nonprocedural clinically relevant bleeding. These data argue that OAC remains the reference for most AF patients eligible for anticoagulation, and LAAC should be reserved for carefully selected patients.
Impact: This synthesis of randomized evidence directly informs a common clinical decision—device versus pharmacologic stroke prevention in AF—and challenges assumptions of LAAC equivalence.
Clinical Implications: For AF patients who can take OAC, OAC should remain first-line. LAAC may be considered for those with contraindications/intolerance to OAC, with explicit counseling about increased ischemic risk despite reduced nonprocedural bleeding.
Key Findings
- LAAC increased ischemic stroke or systemic embolism compared with OAC (RR 1.41, 95% CI 1.07–1.86).
- No significant differences between LAAC and OAC for any stroke/systemic embolism, all-cause or cardiovascular mortality, major bleeding, or hemorrhagic stroke.
- LAAC reduced nonprocedural clinically relevant bleeding versus OAC (RR 0.50, 95% CI 0.43–0.59).
Methodological Strengths
- Random-effects meta-analysis of six RCTs (n=7004) with prespecified outcomes
- Certainty of evidence appraised using GRADE across endpoints
Limitations
- Heterogeneity in devices, anticoagulant comparators (warfarin vs DOAC), and periprocedural protocols
- Potential learning-curve and operator/procedural variability; variable follow-up durations
Future Directions: Head-to-head trials versus contemporary DOAC strategies, subgroup identification (e.g., high bleeding risk), standardized periprocedural management, and device refinements focused on reducing ischemic events.
AIMS: Left atrial appendage closure (LAAC) has emerged as an alternative to oral anticoagulation (OAC) for stroke prevention in atrial fibrillation (AF), but its long-term comparative efficacy remains uncertain. This systematic review and meta-analysis evaluated randomized controlled trials (RCTs) comparing LAAC with OAC in AF. METHODS AND RESULTS: MEDLINE, Embase, Scopus, and the Cochrane Database of Systematic Reviews were searched through 8 April 2026. Risk ratios (RR) with 95% confidence intervals (CI) were pooled using random-effects models. Certainty of evidence (CoE) was assessed using GRADE. Six RCTs involving 7004 participants were included (3681 assigned to LAAC and 3323 to OAC). Compared with OAC, LAAC resulted in a significantly higher risk of ischaemic stroke or systemic embolism (134 vs. 80 events; RR 1.41, 95% CI 1.07-1.86; moderate CoE). No significant differences were observed for any stroke or systemic embolism (RR 1.10, 95% CI 0.87-1.39; moderate CoE), all-cause mortality (RR 0.92, 95% CI 0.77-1.10; high CoE), cardiovascular mortality (RR 0.90, 95% CI 0.67-1.21; moderate CoE), non-cardiovascular mortality (RR 0.92, 95% CI 0.75-1.12; moderate CoE), major bleeding (RR 0.91, 95% CI 0.77-1.08; high CoE), or haemorrhagic stroke (RR 0.58, 95% CI 0.28-1.17; moderate CoE). LAAC reduced the risk of nonprocedural clinically relevant bleeding compared with OAC (RR 0.50, 95% CI 0.43-0.59; high CoE). CONCLUSION: In patients with AF, LAAC results in a higher risk of ischaemic stroke or systemic embolism than an OAC-based strategy. Compared with OAC, LAAC has no effect on major bleeding or mortality and does not reduce haemorrhagic stroke.